The Greatest Guide To P-gb-IN-1
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage multiple intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal demo goals ended up to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyosi